CN106138091A - A kind of pharmaceutical composition preventing and treating bovine mastitis and preparation method thereof - Google Patents
A kind of pharmaceutical composition preventing and treating bovine mastitis and preparation method thereof Download PDFInfo
- Publication number
- CN106138091A CN106138091A CN201610718141.6A CN201610718141A CN106138091A CN 106138091 A CN106138091 A CN 106138091A CN 201610718141 A CN201610718141 A CN 201610718141A CN 106138091 A CN106138091 A CN 106138091A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- water
- polyvinyl alcohol
- preparation
- iodine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 208000031462 Bovine Mastitis Diseases 0.000 title claims abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 38
- 239000000203 mixture Substances 0.000 claims abstract description 19
- 239000000645 desinfectant Substances 0.000 claims abstract description 14
- 239000007788 liquid Substances 0.000 claims abstract description 10
- 239000003906 humectant Substances 0.000 claims abstract description 9
- 239000007787 solid Substances 0.000 claims abstract description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 42
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims description 39
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 31
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 31
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 22
- 239000011630 iodine Substances 0.000 claims description 22
- 229910052740 iodine Inorganic materials 0.000 claims description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 21
- 241000283690 Bos taurus Species 0.000 claims description 16
- 238000002156 mixing Methods 0.000 claims description 16
- DTTVNCZEOYSFFF-UHFFFAOYSA-N ethoxyurea Chemical group CCONC(N)=O DTTVNCZEOYSFFF-UHFFFAOYSA-N 0.000 claims description 13
- 108010020346 Polyglutamic Acid Proteins 0.000 claims description 11
- 229940069521 aloe extract Drugs 0.000 claims description 11
- 229920002643 polyglutamic acid Polymers 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- 208000004396 mastitis Diseases 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- 238000010438 heat treatment Methods 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 7
- 238000004090 dissolution Methods 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 6
- 239000000865 liniment Substances 0.000 claims description 5
- 229940040145 liniment Drugs 0.000 claims description 5
- 238000007654 immersion Methods 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 244000144977 poultry Species 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 claims 2
- 230000000844 anti-bacterial effect Effects 0.000 claims 1
- 230000001954 sterilising effect Effects 0.000 claims 1
- 210000002445 nipple Anatomy 0.000 description 23
- 238000012360 testing method Methods 0.000 description 15
- 239000000243 solution Substances 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- 239000008267 milk Substances 0.000 description 7
- 235000013336 milk Nutrition 0.000 description 7
- 210000004080 milk Anatomy 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000008399 tap water Substances 0.000 description 5
- 235000020679 tap water Nutrition 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 4
- 239000010408 film Substances 0.000 description 4
- 239000012362 glacial acetic acid Substances 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 3
- 241000780272 Mammilla Species 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 2
- 229920000153 Povidone-iodine Polymers 0.000 description 2
- 208000006981 Skin Abnormalities Diseases 0.000 description 2
- -1 and in prescription Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229910003460 diamond Inorganic materials 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 238000007598 dipping method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229960001621 povidone-iodine Drugs 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000002268 wool Anatomy 0.000 description 2
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 1
- 208000009043 Chemical Burns Diseases 0.000 description 1
- 208000018380 Chemical injury Diseases 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010023335 Keratitis interstitial Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- HKGOXNDKLYONQU-UHFFFAOYSA-N [Cl].C(C)(=O)OO Chemical compound [Cl].C(C)(=O)OO HKGOXNDKLYONQU-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 201000006904 interstitial keratitis Diseases 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- NALMPLUMOWIVJC-UHFFFAOYSA-N n,n,4-trimethylbenzeneamine oxide Chemical compound CC1=CC=C([N+](C)(C)[O-])C=C1 NALMPLUMOWIVJC-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000003918 potentiometric titration Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012372 quality testing Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 239000011697 sodium iodate Substances 0.000 description 1
- 235000015281 sodium iodate Nutrition 0.000 description 1
- 229940032753 sodium iodate Drugs 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/18—Iodine; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Botany (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a kind of pharmaceutical composition preventing and treating bovine mastitis, containing following component in the every 1000mL of described compositions: film former 4 8g, disinfectant 10 20g, skin protectant 10mL, solid humectant 1g, liquid humectants 250 600mL, surplus is water.The present composition can effectively prevent and treat bovine mastitis；And good stability, nonirritant, preparation cost is low, and potential applicability in clinical practice is good.
Description
Technical field
The invention belongs to field of veterinary, be specifically related to a kind of pharmaceutical composition preventing and treating bovine mastitis and preparation side thereof
Method.
Background technology
Mastitis are modal diseases in lactating livestock, and the milk yield and the milk quality that show as ill domestic animal significantly drop
Low, mastitis the most all can bring, to dairy industry, the economic loss that tool is big, especially headed by bovine mastitis.Bovine mastitis is milk
One of disease that cattle is most common, the most multiple in producing, its sickness rate accounts for first of the various disease of milch cow.Mastitis severe patient is even also
Affecting oestrusing and gestation of milch cow, some sick cattle significantly reduces because of milk production or loses milking capacity and be forced to eliminate.How to have
Effect prevention mastitis have become as a kind of world subject.
At present, the prevention of bovine mastitis uses the method such as sanitation and hygiene, nipple dipping mostly.Sanitation and hygiene are the most former
Beginning, simplest method, the place touching cowshed and cow breast need to often clean, and breast and nipple need to often be scrubbed, this
Kind of method is higher to environmental condition and cattle body hygienic requirements, needs to consume substantial amounts of human and material resources, financial resources, and pathogen pole
Easily invade, cause breast to be fallen ill.Nipple dipping is the method that current clinic commonly uses, and Medicatedbath lotion conventional clinically has iodine
Attached, hibitane, chlorine peracetic acid, sodium hypochlorite etc., but there is disinfection and hold time short, bigger to mammilla of milk cattle zest
Problem, as medicine has stimulation to skin of nipple, easily cause skin of nipple to chap, on the contrary mammilla of milk cattle damaged.
Also there are now the medicine report of some prevention bovine mastitis, the patent Shen of such as Publication No. CN102429921A
Please provide a kind of mammilla of milk cattle protective agent, this protective agent is by film former polyvinyl alcohol 1799, disinfectant povidone iodine, skin moistening
Wetting agent glycerol, stabilizer sodium iodide and sodium iodate, the medical alcohol of synergist 75% and glacial acetic acid are made.This patent application makes
With having bigger irritating glacial acetic acid, contact skin glacial acetic acid, the lighter occurs that erythema, severe one cause chemical burn, for a long time
Or contact easily causes dermatitis, the glacial acetic acid of contact high concentration repeatedly, can cause interstitial keratitis.
The patent application of Publication No. CN104257684A provides a kind of nipple film coating agent preventing bovine mastitis, should
Liniment is prepared from by 10 plurality of raw materials such as film former polyvinyl alcohol, disinfectant povidone iodine, and in prescription, raw material is many, is prepared as
This height.
The patent application of Publication No. CN101804069A provides a kind of disinfectant for nipples of dairy cows, and this disinfectant solution is by iodine
The raw materials such as lytic agent, skin protectant, stabilizer are prepared from, and must be added to stabilizer, and clinical application effect is not in this formula
Clearly.
Summary of the invention
It is an object of the invention to provide a kind of pharmaceutical composition preventing and treating bovine mastitis and its production and use.
The invention provides a kind of pharmaceutical composition preventing and treating bovine mastitis, containing such as in the every 1000mL of described compositions
Lower component:
Film former 4-8g, disinfectant 10-20g, skin protectant 10mL, solid humectant 1g, liquid humectants 250-
600mL, surplus is water.
Wherein, described film former is polyvinyl alcohol；Described disinfectant is iodine and/or potassium iodide；Described skin protectant is
Aloe extract；Described solid humectant is polyglutamic acid；Described liquid humectants is ethoxy urea and/or glycerol.
Further, described polyvinyl alcohol is PVA and/or polyvinyl alcohol 17-50；Described Aloe extract
Purchased from Ze Bang bio tech ltd, Xi'an.
Wherein, containing following component in the every 1000mL of described compositions:
PVA 1-2g, polyvinyl alcohol 17-50 3-6g, iodine 5-10g, potassium iodide 5-10g, skin protectant 10mL,
Polyglutamic acid 1g, ethoxy urea 50-200mL, glycerol 200-400mL, surplus is water.
Wherein, containing following component in the every 1000mL of described compositions:
PVA 1-2g, polyvinyl alcohol 17-50 3-6g, iodine 5-10g, potassium iodide 5-10g, skin protectant 10mL,
Polyglutamic acid 1g, ethoxy urea 50-200mL, glycerol 200-400mL, ethanol 40-80mL, surplus is water.
Ethanol does cosolvent effect, dissolves iodine.
Wherein, described preparation is external preparation.
Further, the dosage form of described external preparation is preserved material, unguentum, powder, paste, spray, liniment, gel
Agent, liniment.
Present invention also offers the preparation method of aforementioned pharmaceutical compositions, it comprises the steps:
A, weigh each component by proportioning；
B, it is prepared as membrane: take PVA, polyvinyl alcohol 17-50, soak respectively, heating in water bath so that it is
Fully dissolve；Then filter, dry in the air cool, by two kinds of solution mixing, standby；
C, prepare disinfectant: after taking potassium iodide water dissolution, add ethanol and stir；It is subsequently adding iodine to dissolve,
Standby；
D, take after polyglutamic acid water fully dissolves standby；
E, addition ethoxy urea, glycerol, Aloe extract mixing, finally add water constant volume,.
Wherein, in step b, the time of described immersion is 24 hours；The condition of described heating in water bath is: 96 DEG C, and 2.5 is little
Time.
Present invention also offers above-mentioned composition purposes in the medicine of preparation preventing and treating poultry mastitis.
Further, described medicine is the medicine of prevention mammitis of cow.
The present composition, can eliminate the pathogenic bacteria of teat skin surface, can keep again the moistening of skin, moreover it is possible at skin
Surface forms thin film, forms barrier, have good prevention and therapeutic effect to bovine mastitis between nipple and environment；
Said preparation is stable, definite effect, nonirritant, and the most economical and the most practical, and cost is relatively low, is suitable for being widely used.
Obviously, according to the foregoing of the present invention, according to ordinary technical knowledge and the customary means of this area, without departing from
Under the present invention above-mentioned basic fundamental thought premise, it is also possible to make the amendment of other various ways, replace or change.
The detailed description of the invention of form by the following examples, remakes the most specifically the foregoing of the present invention
Bright.But this should not being interpreted as, the scope of the above-mentioned theme of the present invention is only limitted to Examples below.All based on foregoing of the present invention
The technology realized belongs to the scope of the present invention.
Detailed description of the invention
It is described further with embodiment below, but the present invention is not limited to these embodiments.
Experiment reagent used by the present invention is as follows with instrument:
Polyvinyl alcohol: Shandong Su Nuoke Chemical Industry Science Co., Ltd
Iodine: Jinan century sensible Chemical Co., Ltd.
Potassium iodide: Shanghai nine Chemical Co., Ltd. of nation
Aloe extract: Ze Bang bio tech ltd, Xi'an
Polyglutamic acid: dream bio tech ltd, Zhejiang one
Glycerol: Sichuan Ovrette chemical reagent company limited
Ethoxy urea: Guangzhou rain and dew Chemical Co., Ltd.
The preparation of embodiment 1 present composition
Step is as follows:
1, it is prepared as membrane: 1g PVA, 3g polyvinyl alcohol 17-50 are added 50ml, 150ml distilled water respectively
Soak 24 hours, 96 DEG C of heating in water bath 2.5 hours, and be stirred continuously so that it is fully dissolve, filter and remove impurity removing, dry in the air cool, then
By two kinds of solution mixing for standby use；
2, disinfectant is prepared: after taking 5g potassium iodide 20ml water dissolution, add 40ml ethanol and stir, finally
Add the stirring of 5g iodine and fully dissolve standby；
3, take after 1g polyglutamic acid 20ml water fully dissolves standby；
4,150ml ethoxy urea, 200ml glycerol, 10ml Aloe extract are taken, by three's mixing for standby use；
Finally above-mentioned four kinds of liquid mixing being stirred, the constant volume that adds water is 1000ml, uses as nipple extractum.
The preparation of embodiment 2 present composition
Step is as follows:
1, it is prepared as membrane: 2g PVA, 6g polyvinyl alcohol 17-50 are added respectively the distillation of 50ml, 150ml
Water soaking 24 hours, 96 DEG C of heating in water bath 2.5 hours, and be stirred continuously so that it is fully dissolve, filter and remove impurity removing, dry in the air cool, so
After by two kinds of solution mixing for standby use；
2, prepare disinfectant: after taking 10g potassium iodide 40ml water dissolution, then add the stirring of 80ml ethanol to the inside all
Even, it is eventually adding the stirring of 10g iodine and fully dissolves standby；
3, take after 1g polyglutamic acid water fully dissolves standby；
4,100ml ethoxy urea, 300ml glycerol, 10ml Aloe extract are taken, by three's mixing for standby use；
Finally above-mentioned four kinds of liquid mixing being stirred, the constant volume that adds water is 1000ml.
The preparation of embodiment 3 present composition
Step is as follows:
1, it is prepared as membrane: 1.5g PVA, 4.5g polyvinyl alcohol 17-50 are added 50ml, 150ml respectively
Distilled water immersion 24 hours, 96 DEG C of heating in water bath 2.5 hours, and be stirred continuously so that it is fully dissolve, filter and remove impurity removing, dry in the air
Cool, then by two kinds of solution mixing for standby use；
2, prepare disinfectant: after taking 10g potassium iodide 40ml water dissolution, then add the stirring of 80ml ethanol to the inside all
Even, it is eventually adding the stirring of 10g iodine and fully dissolves standby；
3, take after 1g polyglutamic acid water fully dissolves standby；
4,50ml ethoxy urea, 400ml glycerol, 10ml Aloe extract are taken, by three's mixing for standby use；
Finally above-mentioned four kinds of liquid mixing being stirred, the constant volume that adds water is 1000ml.
The preparation of embodiment 4 present composition
Step is as follows:
1, it is prepared as membrane: 1.5g PVA, 4.5g polyvinyl alcohol 17-50 are added 50ml, 150ml respectively
Distilled water immersion 24 hours, 96 DEG C of heating in water bath 2.5 hours, and be stirred continuously so that it is fully dissolve, filter and remove impurity removing, dry in the air
Cool, then by two kinds of solution mixing for standby use；
2, prepare disinfectant: after taking 10g potassium iodide 40ml water dissolution, then add the stirring of 80ml ethanol to the inside all
Even, it is eventually adding the stirring of 10g iodine and fully dissolves standby；
3, take after 1g polyglutamic acid water fully dissolves standby；
4,200ml ethoxy urea, 400ml glycerol, 10ml Aloe extract are taken, by three's mixing for standby use；
Finally above-mentioned four kinds of liquid mixing being stirred, the constant volume that adds water is 1000ml.
Beneficial effects of the present invention is illustrated below by way of test example:
The quality testing of test example 1 nipple of the present invention preserved material
1, character:
The supernatant liquid that nipple preserved material is rufous of the embodiment of the present invention 1 preparation, has the special smell of iodine and ethanol.
2, stability test
Take the nipple preserved material prepared to be sub-packed in the vial of 500ml, respectively at room temperature lucifuge and refrigerator (0 DEG C～5
DEG C) store, every 7d routine observation.
Result shows, the nipple extractum of the present invention was layered, without metachromatism, good stability without precipitation, nothing in 12 months.
3, content of iodine detection
Content of iodine detection method: take this product 20g, the most weighed, put in iodine flask, add water 100ml.According to potentiometric titration, use
Sodium thiosulfate volumetric solution (0.1mol/L) titrates.Every 1ml sodium thiosulfate volumetric solution (0.1mol/L) is equivalent to 12.69mg's
Iodine.Separately take this product, measure relative density simultaneously, be milliliter number by the conversion of test sample weight, calculate, to obtain final product.By every for sample monthly test
Surveying once, the content of the continuous detecting result iodine of 12 months is: 1.018%, 1.016%, 1.016%, 1.012%,
1.012%, 1.010%, 1.007%, 1.007%, 1.004%, 1.003%, 1.001%, 1.000%.
Result shows, the active substance stable content of nipple extractum of the present invention, undegraded, good stability.
To sum up, nipple extract product good stability of the present invention.
The irritation test of test example 2 nipple of the present invention preserved material
1, test is once smeared:
Taking healthy adult rabbit 12, average weight is 2.0 ± 0.2kg, and male and female do not limit, and shaves light man rabbit back diamond wool
10cm2, the nipple preserved material of Example 1 preparation and each 2ml of tap water, it is evenly coated at a shaving of rabbit back both sides respectively,
In being administered 1,2,4,8,16,32,64, observe dermoreaction after 128h.
As a result, smear position all to react without the skin abnormality such as erythema, vesicle.
2, test is smeared continuously:
Taking other healthy adult rabbit 12, average weight is 2.0 ± 0.2kg, and male and female do not limit, and shaves light man rabbit back diamond wool
10cm2, the nipple preserved material of Example 1 preparation and each 2ml of tap water, every day 2 times, each interval time is 12 hours, respectively
In being evenly coated at a shaving of rabbit back both sides, continuous 10d observes dermoreaction.
As a result, smear position all to react without the skin abnormality such as erythema, vesicle.
This test illustrates, product nonirritant of the present invention can be used safely.
Test example 3 present composition is to the controlling experiment of bovine mastitis and result
At the cattle farm present composition, mammitis of cow is carried out preventive effect comparative test.
Selecting 300 essentially identical cow heads of health status (same cowshed), wherein 100 cow heads are tested group, 100
Comparing group, do blank other 100 first year, test is to carry out in the case of normal production, manual milking, every day two
Secondary, test group and matched group feeding and management and sanitary condition are basically identical.
Test group: nipple preserved material tap water embodiment 1 prepared dilutes twice, in one minute after of every time milking all
Spread upon in skin of nipple and papillary foramina depression evenly；
Matched group: take 10% betagen solution, after tap water dilution twice, in one minute after of every time milking uniformly
Spread upon skin of nipple and papillary foramina depression in；
Blank group: only with tap water by nipple wiped clean.
Use the sickness rate of LMT diagnosticum monitoring mastitis, the results are shown in Table 1 in medication after three months.
Results contrast before and after table 1 test
From table 1, the present composition can effectively reduce the sickness rate of bovine mastitis, and effect is better than the poly-dimension of positive drug
Ketone iodine, has good prevention and therapeutic effect to bovine mastitis.
To sum up, the present composition, can effectively prevent and treat bovine mastitis；And good stability, nonirritant, system
Standby low cost, potential applicability in clinical practice is good.
Claims (10)
1. the pharmaceutical composition preventing and treating bovine mastitis, it is characterised in that: containing as follows in the every 1000mL of described compositions
Component:
Film former 4-8g, disinfectant 10-20g, skin protectant 10mL, solid humectant 1g, liquid humectants 250-600mL,
Surplus is water.
Pharmaceutical composition the most according to claim 1, it is characterised in that: described film former is polyvinyl alcohol；Described sterilization
Antibacterial is iodine and/or potassium iodide；Described skin protectant is Aloe extract；Described solid humectant is polyglutamic acid；Described liquid
Body wetting agent is ethoxy urea and/or glycerol.
Pharmaceutical composition the most according to claim 1, it is characterised in that:
Described polyvinyl alcohol is PVA and/or polyvinyl alcohol 17-50；
Described Aloe extract is purchased from Ze Bang bio tech ltd, Xi'an.
Pharmaceutical composition the most according to claim 3, it is characterised in that: containing following group in the every 1000mL of described compositions
Point:
PVA 1-2g, polyvinyl alcohol 17-50 3-6g, iodine 5-10g, potassium iodide 5-10g, skin protectant 10mL, poly-paddy
Propylhomoserin 1g, ethoxy urea 50-200mL, glycerol 200-400mL, surplus is water.
5. according to the pharmaceutical composition described in claim 1-4 any one, it is characterised in that: in the every 1000mL of described compositions
Containing following component:
PVA 1-2g, polyvinyl alcohol 17-50 3-6g, iodine 5-10g, potassium iodide 5-10g, skin protectant 10mL, poly-paddy
Propylhomoserin 1g, ethoxy urea 50-200mL, glycerol 200-400mL, ethanol 40-80mL, surplus is water.
6. according to the pharmaceutical composition described in claim 1-5 any one, it is characterised in that: described preparation is external preparation.
Pharmaceutical composition the most according to claim 6, it is characterised in that: the dosage form of described external preparation be preserved material, unguentum,
Powder, paste, spray, liniment, gel, liniment.
8. the preparation method of pharmaceutical composition described in claim 1-7 any one, it is characterised in that: it comprises the steps:
A, weigh each component by proportioning；
B, it is prepared as membrane: take PVA, polyvinyl alcohol 17-50, soak respectively, heating in water bath so that it is fully
Dissolve；Then filter, dry in the air cool, by two kinds of solution mixing, standby；
C, prepare disinfectant: after taking potassium iodide water dissolution, add ethanol and stir；It is subsequently adding iodine to dissolve, standby；
D, take after polyglutamic acid water fully dissolves standby；
E, addition ethoxy urea, glycerol, Aloe extract mixing, finally add water constant volume,.
Wherein, in step b, the time of described immersion is 24 hours；The condition of described heating in water bath is: 96 DEG C, 2.5 hours.
9. the purposes in the medicine of preparation preventing and treating poultry mastitis of the compositions described in claim 1-7 any one.
Purposes the most according to claim 9, it is characterised in that: described medicine is the medicine of prevention mammitis of cow.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610718141.6A CN106138091A (en) | 2016-08-24 | 2016-08-24 | A kind of pharmaceutical composition preventing and treating bovine mastitis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610718141.6A CN106138091A (en) | 2016-08-24 | 2016-08-24 | A kind of pharmaceutical composition preventing and treating bovine mastitis and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106138091A true CN106138091A (en) | 2016-11-23 |
Family
ID=57342709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610718141.6A Pending CN106138091A (en) | 2016-08-24 | 2016-08-24 | A kind of pharmaceutical composition preventing and treating bovine mastitis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106138091A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106138220A (en) * | 2016-08-05 | 2016-11-23 | 中国农业科学院兰州畜牧与兽药研究所 | A kind of dairy cattle during nonlactating nipple external application protection medicine film and its preparation method and application |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6379685B1 (en) * | 1997-09-26 | 2002-04-30 | Ecolab Inc. | Acidic aqueous chlorite teat dip with improved emollient providing shelf life, sanitizing capacity and tissue protection |
| CN102429921A (en) * | 2011-04-06 | 2012-05-02 | 保全福 | Breast protection film (cow nipple protective agent) |
| CN102973601A (en) * | 2012-12-26 | 2013-03-20 | 哈尔滨五牛生物技术开发有限公司 | Medicated bath film forming agent for preventing bouine mastitis and preparation method of medicated bath film forming agent |
| CN104257684A (en) * | 2014-09-17 | 2015-01-07 | 黑龙江省兽医科学研究所 | Medicated bath liniment for cow nipples and preparation method of medicated bath liniment |
| CN105168239A (en) * | 2015-09-07 | 2015-12-23 | 山东大学 | Breast protection membrane for preventing dairy cow mastitis and preparing process of breast protection membrane |
| CN105853397A (en) * | 2016-04-26 | 2016-08-17 | 上海宇昂新材料科技有限公司 | Povidone iodine concentrated solution as well as preparation method and application thereof |
-
2016
- 2016-08-24 CN CN201610718141.6A patent/CN106138091A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6379685B1 (en) * | 1997-09-26 | 2002-04-30 | Ecolab Inc. | Acidic aqueous chlorite teat dip with improved emollient providing shelf life, sanitizing capacity and tissue protection |
| CN102429921A (en) * | 2011-04-06 | 2012-05-02 | 保全福 | Breast protection film (cow nipple protective agent) |
| CN102973601A (en) * | 2012-12-26 | 2013-03-20 | 哈尔滨五牛生物技术开发有限公司 | Medicated bath film forming agent for preventing bouine mastitis and preparation method of medicated bath film forming agent |
| CN104257684A (en) * | 2014-09-17 | 2015-01-07 | 黑龙江省兽医科学研究所 | Medicated bath liniment for cow nipples and preparation method of medicated bath liniment |
| CN105168239A (en) * | 2015-09-07 | 2015-12-23 | 山东大学 | Breast protection membrane for preventing dairy cow mastitis and preparing process of breast protection membrane |
| CN105853397A (en) * | 2016-04-26 | 2016-08-17 | 上海宇昂新材料科技有限公司 | Povidone iodine concentrated solution as well as preparation method and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| 刘霞等: "聚谷氨酸的保湿功效及安全性评价", 《日用化学工业》 * |
| 朱丽君等: "芦荟治疗急性乳腺炎15例", 《JOURNAL OF EXTERNAL THERAPY OF TCM》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106138220A (en) * | 2016-08-05 | 2016-11-23 | 中国农业科学院兰州畜牧与兽药研究所 | A kind of dairy cattle during nonlactating nipple external application protection medicine film and its preparation method and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103027857B (en) | Shampoo containing marine biological degerming components and preparation method of shampoo | |
| CN104013573B (en) | Available iodine content is the liquid PVP-I of 5-12% | |
| CN104622792A (en) | Film-forming papilla medicated bath preparation used for controlling recessive mastitis of dairy cattle | |
| CN102113981B (en) | A kind of non-rinsing pregnant woman's perineal medical care gel and preparation method thereof | |
| CN104257684B (en) | Milk cow nipple medicated bath plastics and preparation method thereof | |
| CN108836938B (en) | Environment-friendly composite foam hoof bath lotion and preparation method thereof | |
| CN102405935B (en) | Protamine compounded preparation, preparation method and application thereof | |
| CN105582538A (en) | Drip-proof type dairy cow teat dipping solution and preparation method thereof | |
| CN114652767B (en) | Dairy cow nipple medicated bath agent and preparation method thereof | |
| Krupelnytskyi | Hygiene products for udder health of lactating cows | |
| CN104798775B (en) | A kind of cationic surfactant composite disinfectant for animals | |
| RU2537143C1 (en) | Preparation for treatment and prevention of mastitis in cows | |
| CN106798749B (en) | Povidone-iodine film-forming disinfectant and preparation method and application thereof | |
| CN106138091A (en) | A kind of pharmaceutical composition preventing and treating bovine mastitis and preparation method thereof | |
| CN102429921A (en) | Breast protection film (cow nipple protective agent) | |
| JP2006050911A (en) | Teat pack, teat protection method and teat pack application method. | |
| CN102552317B (en) | Iodine glycerol nipple infusion and preparation method thereof | |
| CN115777725B (en) | Nano silver disinfectant and preparation method thereof | |
| CN114159463A (en) | A kind of moisturizing iodine glycerin teat infusion and preparation method thereof | |
| CN102846489B (en) | Polyhexamethyleneguanidine hydrochloride iodine medicine bath liquid and preparation method thereof | |
| CN107753937A (en) | A kind of wound disinfection agent and preparation method thereof | |
| CN106236835A (en) | A kind of plants essential oil spray and its preparation method and application | |
| CN109846847B (en) | Effervescent tablet for treating animal dermatosis and preparation method thereof | |
| CN102961331A (en) | Iodine-chitosan solution formula and preparation method thereof | |
| CN113288913A (en) | Povidone iodine solution and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161123 |